Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells ; volume:24 ; number:1 ; day:12 ; month:8 ; year:2024 ; pages:1-14 ; date:12.2024
Cancer cell international ; 24, Heft 1 (12.8.2024), 1-14, 12.2024
- Urheber
-
Romaniuk-Drapala, Aleksandra
Skupin-Mrugalska, Paulina
Garbuzenko, Olga
Hatefi, Arash
Minko, Tamara
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03469-0
- URN
-
urn:nbn:de:101:1-2410310837591.671003350933
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Romaniuk-Drapala, Aleksandra
- Skupin-Mrugalska, Paulina
- Garbuzenko, Olga
- Hatefi, Arash
- Minko, Tamara
- SpringerLink (Online service)
Ähnliche Objekte (12)
Studies on the skin penetration mechanisms of liposomal formulations
Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Development of Proliposomal and Liposomal Formulations with Poorly Water-soluble Drugs
Liposomal Enzyme Nanoreactors Based on Nanoconfinement for Efficient Antitumor Therapy
Liposomal formulations for the oral delivery of the pharmaceutically active peptide exenatide
Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy
Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout
TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Development and in vitro testing of liposomal gadolinium-formulations for neutron capture therapy of glioblastoma multiforme
Development and in vitro testing of liposomal gadolinium-formulations for neutron capture therapy of glioblastoma multiforme
Studies on the skin penetration mechanisms of liposomal formulations
Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Development of Proliposomal and Liposomal Formulations with Poorly Water-soluble Drugs
Liposomal Enzyme Nanoreactors Based on Nanoconfinement for Efficient Antitumor Therapy
Liposomal formulations for the oral delivery of the pharmaceutically active peptide exenatide
Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy
Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout
TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Development and in vitro testing of liposomal gadolinium-formulations for neutron capture therapy of glioblastoma multiforme
Development and in vitro testing of liposomal gadolinium-formulations for neutron capture therapy of glioblastoma multiforme
Studies on the skin penetration mechanisms of liposomal formulations
Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Development of Proliposomal and Liposomal Formulations with Poorly Water-soluble Drugs
Liposomal Enzyme Nanoreactors Based on Nanoconfinement for Efficient Antitumor Therapy
Liposomal formulations for the oral delivery of the pharmaceutically active peptide exenatide
Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy
Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout
TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Development and in vitro testing of liposomal gadolinium-formulations for neutron capture therapy of glioblastoma multiforme